A Phase 2 interventional study of PF-00547659 SC injection and PF-00547659 SC injection in Crohn's Disease, sponsored by Shire. Completed at 137 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-03.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Crohn Disease by Takeda — 12 open to participants now, 14 under way, 7 of them phase 3. Crohn Disease · Takeda.
Among the 86 studies in Crohn Disease by Takeda, this one is the 14th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2011, is one of 13 in phase 2, and was the 9th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →12 of the 86 studies in Crohn Disease by Takeda are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United Kingdom
Ages 18–75
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States, China, Czechia and 5 more countries
Ages 18–75
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 25 · Phase 4 10
First in 2000; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 265 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 100 across the 51 interventional studies, 319 across the 34 observational. Of the 66 that completed or were terminated, 37 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
6 of the studies in Crohn Disease by Takeda that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
| NCT06233461TakedaA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | 2027-02-17 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06045754TakedaA Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | 2027-06-28 |
Add all 6 to your calendar (.ics) → With an account.
Among the 86 studies in Crohn Disease by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Adults with Crohn's disease that is clinically active despite conventional treatment will be eligible for this study. Patients may receive one of three doses of PF-00547659 (experimental drug) or placebo (inactive drug). Disease activity will be measured every two weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo delivered SC, 3 doses separated by 4 weeks.
Drug: PF-00547659 SC injection
Drug dose level 1 delivered SC, 3 doses separated by 4 weeks.
Drug: PF-00547659 SC injection
Drug dose level 2 delievered SC, 3 doses separated by 4 weeks.
Drug: PF-00547659 SC injection
Drug dose level 3 delivered SC, 3 doses separated by 4 weeks.
Drug: PF-00547659 SC injection
Placebo delivered SC, 3 doses separated by 4 weeks
Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate
Crohn's Disease Activity Index (CDAI) is a number which consists of information collected from a 7-day diary from the participants regarding symptoms. Remission is considered a score of 150 or less. Active disease is considered 200 or greater. A response to therapy is considered a decline in CDAI score of 70-points from baseline. CDAI response rate at week 8 and week 12 was measured between the investigational product group and the placebo group.
Time frame: Week 8 and week 12
Safety and Tolerability of PF-00547659 Dose Levels Versus Placebo
Number of participants with adverse events (AEs), withdrawals due to AEs and Serious AEs (SAEs) were reported.
Time frame: Week 0-12
Number of Adverse Events (AEs) - PF-00547659 Dose Levels Versus Placebo
Number of adverse events (all causalities and treatment related) was reported between the investigational product groups and the placebo group.
Time frame: Week 0-12
Percentage of Participants With a Crohn's Disease Activity Index (CDAI) Remission
Percentage of participants with a CDAI remission (defined as a CDAI reduction to \<150 points).
Time frame: Weeks 8 and week 12
Crohn's Disease Activity Index (CDAI)-70 Response Rates Over Time
Percentage of participants with Crohn's Disease Activity Index (CDAI)-70 response were reported.
Time frame: Week 2, 4, 6, 8, 10 and 12
Crohn's Disease Activity Index (CDAI) -100 Response Rates Over Timer
Percentage of participants with Crohn's Disease Activity Index (CDAI)-100 response were reported.
Time frame: Week 2, 4, 6, 8, 10 and 12
Immunogenicity Assessment of Anti-drug Antibodies (ADAs)
Confirmed cumulative incidence of anti-drug antibodies development to PF-00547659
Time frame: Day 1, Week 4, Week 8, Week 12, Week 20, Week 28, Week 36
The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)
The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to area under the concentration-time profile (AUC), clearance (CL) and half life were estimated using data pooled from both typical and additional PK groups. AUCinf is area under the concentration time profile from time zero extrapolated to infinite time.
Time frame: Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252
The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero to Time Tau (AUCtau)
The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. AUCtau is area under the concentration time profile from time zero to time tau, the dosing interval, where tau = 672 hours (4 weeks)
Time frame: Day 1, 14, and 28
The Pharmacokinetics (PK) of Total PF-00547659 - Maximum Observed Concentration (Cmax)
The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Cmax is maximum observed concentration.
Time frame: Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252
The Pharmacokinetics (PK) of Total PF-00547659 - Time for Cmax (Tmax)
The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Tmax is time for Cmax.
Time frame: Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252
The Pharmacokinetics (PK) of Total PF-00547659 - Terminal Half Life (Thalf)
The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Thalf is terminal half life.
Time frame: Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252
The Pharmacokinetics (PK) of Total PF-00547659 - Apparent Clearance (CL/F)
The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. CL/F is apparent clearance.
Time frame: Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252
| Milestone | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg | Placebo |
|---|---|---|---|---|
| Started | 66 | 65 | 68 | 63 |
| Completed | 53 | 53 | 63 | 58 |
| Not completed | 13 | 12 | 5 | 5 |
| Withdrew: Adverse event | 9 | 8 | 4 | 3 |
| Withdrew: Lack of efficacy | 2 | 1 | 1 | 2 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
Crohn's Disease Activity Index (CDAI) is a number which consists of information collected from a 7-day diary from the participants regarding symptoms. Remission is considered a score of 150 or less. Active disease is considered 200 or greater. A response to therapy is considered a decline in CDAI score of 70-points from baseline. CDAI response rate at week 8 and week 12 was measured between the investigational product group and the placebo group.
| Percentage of Participants | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg | Placebo |
|---|---|---|---|---|
| Week 8 (n =50, 55, 62, 56) | 52.7 | 60.1 | 62.7 | 47.7 |
| Week 12 (n = 51, 49, 61, 54) | 62.0 | 64.7 | 57.5 | 58.6 |
Number of participants with adverse events (AEs), withdrawals due to AEs and Serious AEs (SAEs) were reported.
| Number of participants | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg | Placebo |
|---|---|---|---|---|
| Participants with AEs (all causalities) | 57 | 51 | 54 | 54 |
| Participants with AEs (treatment related) | 20 | 24 | 29 | 22 |
| Withdrawal due to AEs (all causalities) | 9 | 8 | 4 | 3 |
| Withdrawal due to AEs (treatment related) | 5 | 2 | 0 | 1 |
| Participants with SAEs (all causalities) | 11 | 9 | 11 | 5 |
| Participants with SAEs (treatment related) | 4 | 4 | 2 | 2 |
Number of adverse events (all causalities and treatment related) was reported between the investigational product groups and the placebo group.
| events | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg | Placebo |
|---|---|---|---|---|
| Number of AEs (all causalities) | 175 | 192 | 192 | 141 |
| Number of AEs (treatment related) | 40 | 55 | 64 | 40 |
Percentage of participants with a CDAI remission (defined as a CDAI reduction to \<150 points).
| Percentage of Participants | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg | Placebo |
|---|---|---|---|---|
| Week 8 (n = 50, 56, 62, 57) | 29.1 | 23.8 | 26.9 | 16.7 |
| Week 12 (n= 51, 49, 61, 55) | 26.8 | 28.5 | 29.6 | 23.0 |
Percentage of participants with Crohn's Disease Activity Index (CDAI)-70 response were reported.
| Percentage of Participants | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg | Placebo |
|---|---|---|---|---|
| Week 2 (n = 64, 60, 63, 60) | 35.1 (22.8 to 49.6) | 22.4 (12.9 to 36.0) | 33.8 (21.6 to 48.5) | 35.5 (22.9 to 50.5) |
| Week 4 (n = 58, 60, 65, 58) | 38.0 (24.9 to 53.2) | 39.5 (26.3 to 54.4) | 36.2 (23.7 to 51.0) | 38.3 (25.1 to 53.5) |
| Week 6 (n =56, 54, 64, 58) | 45.3 (31.1 to 60.3) | 53.4 (38.2 to 67.9) | 47.5 (33.3 to 62.1) | 48.0 (33.5 to 62.9) |
| Week 8 (n =50, 55, 62, 56) | 52.7 (37.2 to 67.7) | 60.1 (44.9 to 73.6) | 62.7 (47.9 to 75.4) | 47.7 (33.1 to 62.7) |
| Week 10 (n =50, 48, 60, 52) | 67.4 (52.0 to 79.7) | 58.2 (42.3 to 72.6) | 61.6 (46.8 to 74.6) | 53.0 (37.6 to 67.8) |
| Week 12 (n = 51, 49, 61, 54) | 62.0 (46.5 to 75.3) | 64.7 (48.9 to 77.8) | 57.5 (42.6 to 71.2) | 58.6 (43.3 to 72.4) |
Percentage of participants with Crohn's Disease Activity Index (CDAI)-100 response were reported.
| Percentage of Participants | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg | Placebo |
|---|---|---|---|---|
| Week 2 (n = 64, 60, 63, 60) | 19.3 (10.6 to 32.6) | 18.4 (9.9 to 31.7) | 20.0 (11.0 to 33.6) | 18.5 (9.9 to 31.9) |
| Week 4 (n = 58, 60 ,65, 58) | 29.2 (17.5 to 44.6) | 32.3 (20.0 to 47.5) | 28.2 (17.0 to 43.0) | 29.5 (17.7 to 44.9) |
| Week 6 (n =56, 54, 64, 58) | 40.6 (26.6 to 56.4) | 42.6 (28.2 to 58.5) | 40.4 (26.8 to 55.8) | 39.3 (25.5 to 55.0) |
| Week 8 (n = 50, 55, 62, 56) | 50.5 (34.8 to 66.2) | 48.3 (33.3 to 63.7) | 57.0 (41.8 to 71.0) | 41.4 (27.2 to 57.3) |
| Week 10 (n = 50, 48, 62, 52) | 53.2 (37.3 to 68.5) | 47.4 (31.8 to 63.5) | 50.9 (35.9 to 65.7) | 43.6 (28.7 to 59.7) |
| Week 12 (n = 51, 49, 61, 54) | 56.0 (40.1 to 70.7) | 47.7 (32.2 to 63.7) | 53.8 (38.7 to 68.4) | 44.4 (29.6 to 60.2) |
Confirmed cumulative incidence of anti-drug antibodies development to PF-00547659
| events | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|
| Day 1 (n =46, 52, 53) | 3 | 5 | 1 |
| Week 4 (n = 55, 52, 55) | 2 | 4 | 2 |
| Week 8 (n = 44, 47, 56) | 1 | 1 | 1 |
| Week 12 (n = 47, 51, 51) | 3 | 5 | 1 |
| Week 20 (n = 4, 3, 1) | 0 | 0 | 0 |
| Week 28 (n = 8, 1, 1) | 1 | 0 | 0 |
| Week 36 (n = 6, 2, 1) | 0 | 0 | 0 |
The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to area under the concentration-time profile (AUC), clearance (CL) and half life were estimated using data pooled from both typical and additional PK groups. AUCinf is area under the concentration time profile from time zero extrapolated to infinite time.
| µg•hr/mL | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|
| The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) | 615300 ± 63 | 4464000 ± 28 | 13760000 ± 49 |
The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. AUCtau is area under the concentration time profile from time zero to time tau, the dosing interval, where tau = 672 hours (4 weeks)
| µg•hr/mL | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|
| The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero to Time Tau (AUCtau) | 549500 ± 53 | 4214000 ± 31 | 10850000 ± 45 |
The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Cmax is maximum observed concentration.
| µg/mL | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|
| The Pharmacokinetics (PK) of Total PF-00547659 - Maximum Observed Concentration (Cmax) | 1756 ± 45 | 10800 ± 22 | 24100 ± 47 |
The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Tmax is time for Cmax.
| Hours | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|
| The Pharmacokinetics (PK) of Total PF-00547659 - Time for Cmax (Tmax) | 140 ± 45 | 143 ± 22 | 165 ± 47 |
The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Thalf is terminal half life.
| Day | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|
| The Pharmacokinetics (PK) of Total PF-00547659 - Terminal Half Life (Thalf) | 4.977 ± 2.8435 | 8.770 ± 2.3571 | 12.22 ± 3.8306 |
The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. CL/F is apparent clearance.
| mL/hr | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg |
|---|---|---|---|
| The Pharmacokinetics (PK) of Total PF-00547659 - Apparent Clearance (CL/F) | 36.54 ± 63 | 16.79 ± 28 | 16.38 ± 49 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-00547659 22.5 mg | — | 12/66 (18.2%) | 36/66 (54.5%) |
| PF-00547659 75 mg | — | 11/65 (16.9%) | 32/65 (49.2%) |
| PF-00547659 225 mg | — | 11/68 (16.2%) | 42/68 (61.8%) |
| Placebo | — | 6/63 (9.5%) | 35/63 (55.6%) |
| Event | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg | Placebo |
|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 5/66 | 6/65 | 4/68 | 4/63 |
| AppendicitisInfections and infestations | 2/66 | 0/65 | 0/68 | 0/63 |
| Small intestinal obstructionGastrointestinal disorders | 0/66 | 1/65 | 2/68 | 0/63 |
| Rectal stenosisGastrointestinal disorders | 0/66 | 0/65 | 0/68 | 1/63 |
| PyrexiaGeneral disorders | 0/66 | 1/65 | 1/68 | 1/63 |
| Anal abscessInfections and infestations | 0/66 | 1/65 | 1/68 | 1/63 |
| Fistula of small intestineGastrointestinal disorders | 0/66 | 1/65 | 0/68 | 0/63 |
| Intestinal obstructionGastrointestinal disorders | 0/66 | 1/65 | 0/68 | 0/63 |
| SepsisInfections and infestations | 0/66 | 1/65 | 0/68 | 0/63 |
| Staphylococcal infectionInfections and infestations | 0/66 | 1/65 | 0/68 | 0/63 |
| Event | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg | Placebo |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 5/66 | 6/65 | 8/68 | 7/63 |
| HeadacheNervous system disorders | 6/66 | 3/65 | 8/68 | 6/63 |
| NauseaGastrointestinal disorders | 7/66 | 4/65 | 5/68 | 7/63 |
| Crohn's diseaseGastrointestinal disorders | 5/66 | 7/65 | 1/68 | 5/63 |
| Abdominal painGastrointestinal disorders | 7/66 | 1/65 | 4/68 | 3/63 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/66 | 6/65 | 5/68 | 3/63 |
| NasopharyngitisInfections and infestations | 3/66 | 4/65 | 5/68 | 5/63 |
| Urinary tract infectionInfections and infestations | 2/66 | 1/65 | 3/68 | 5/63 |
| FatigueGeneral disorders | 5/66 | 4/65 | 2/68 | 3/63 |
| Oedema peripheralGeneral disorders | 0/66 | 1/65 | 5/68 | 0/63 |
| Age, Continuous(years) | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 37.3 ± 13.0 | 34.4 ± 10.7 | 35.9 ± 11.0 | 34.4 ± 11.1 | 35.5 ± 11.5 |
| Sex: Female, Male(Participants) | PF-00547659 22.5 mg | PF-00547659 75 mg | PF-00547659 225 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 48 | 35 | 43 | 30 | 156 |
| Male | 18 | 30 | 25 | 33 | 106 |
Showing the first 100 of 137 sites across 16 countries. Choose a country and city above to see the rest.
Ran from Apr 2011 to primary completion in Feb 2014, 34 months.
Results were first posted in Apr 2017, 3 years 2 months after primary completion. A results delay was requested in Feb 2015.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 34 months is close to that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ontamalimab